BioVie says bezisterim shows distinct responses in two Long COVID patient groups

BioVie Inc. reported Phase 2 trial results showing bezisterim had distinct effects on two Long COVID patient groups. High-inflammatory patients improved in cognition, while low white blood cell patients saw fatigue and post-exertional malaise reductions. Bezisterim also lowered NPY levels by 33%. The trial involved 203 participants.

Original reporting
Published Nov 16, 2026, 2:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 3:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BioVie says bezisterim shows distinct responses in two Long COVID patient groups — source image
Decision brief

The 30-second read

$BIVIBullishMed
01

Why it matters

Traders may reassess bezisterim’s development path toward more targeted future trials, using inflammatory biomarkers for cognition and low WBC/myeloid profiles for fatigue and post-exertional malaise.

02

Market read

The article provides new subgroup effect differentiation and biomarker response signals, which can shift expectations for future trial design despite overall non-significance.

03

What to watch

NPY is being added to NIH RECOVER prioritization, but the article stresses it is not yet validated as a diagnostic or predictive biomarker, which could slow translation into trial-ready selection criteria.

Relevance 7/10Novelty 6/10Timing: conference presentation disclosed Nov 13, reported Nov 16

Background

BioVie’s ADDRESS-LC Phase 2 trial evaluated bezisterim in Long COVID and now presents biomarker-defined subgroup analyses at a Long COVID conference.

Company-level read

Ticker impact

$BIVIBullishMedium confidence
Context

BioVie reports Phase 2 ADDRESS-LC exploratory analyses showing two biomarker-defined Long COVID groups respond differently to bezisterim.

Expected impact

Likely modest upside bias as traders price improved probability of future trial success via endotype targeting, tempered by the lack of overall statistical significance.

Evidence & confidence

The article discloses subgroup effect sizes and biomarker-linked endpoint differentiation, plus safety/tolerability comparable to placebo, but explicitly notes the overall population trend did not reach statistical significance.

Market effects

Reinforces the broader Long COVID biotech playbook of biomarker-defined endotypes and endpoint tailoring, which can influence sentiment across the sector.

Limited direct impact beyond US biotech sentiment, since the catalyst is company-specific clinical-trial subgroup analysis.

Moderate relevance for international Long COVID research stakeholders, but unlikely to move global risk appetite.

Counterpoint

Because the findings are exploratory and the overall population did not achieve statistical significance, the market may overestimate the durability of the subgroup signals.

Key entities

  • BioVie Inc

    NASDAQ-listed biotech running Phase 2 ADDRESS-LC for bezisterim in Long COVID.

  • bezisterim

    BioVie’s investigational therapy evaluated in ADDRESS-LC.

  • ADDRESS-LC

    Phase 2 randomized trial of bezisterim versus placebo for 12 weeks in Long COVID.

  • NPY (neuropeptide Y)

    Circulating biomarker reduced by bezisterim by about 33% at Week 12; added to NIH RECOVER prioritization list.

Related articles

$BIVIHighAI 8/10

BioVie to present additional Parkinson’s drug data at international conference

BioVie Inc (BIVI, BIVIW) will present additional data on its experimental Parkinson's drug, bezisterim, at the AD/PD 2027 conference in Barcelona. The data, from the Phase 2 SUNRISE-PD trial, showed significant improvements in motor and non-motor symptoms for patients with higher inflammation. The company reported a 1.23-point improvement in treated patients versus a 1.21-point worsening in the placebo group, with a p-value of 0.0006.

$BIVIMedAI 8/10

BioVie identifies two Long COVID patient groups with distinct responses to bezisterim

BioVie Inc. (BIVI, BIVIW) reported that its Long COVID trial identified two patient groups with distinct responses to its drug bezisterim. High-inflammatory patients showed cognitive improvements, while others improved in fatigue and post-exertional malaise. The trial, involving 203 participants, did not reach statistical significance overall. BioVie plans to present more data at an upcoming conference.

$BIVIMed

BioVie 3Q 2026: EPS ($0.68) — 10-Q Summary

BioVie reported a wider quarterly loss of $5.61M, or $0.68 per share, due to increased R&D expenses and lower interest income. The company is pre-revenue. Key programs, including Parkinson's disease and Long COVID, showed positive results. The Phase 3 liver program protocol is being finalized. According to the company, R&D expenses rose primarily due to the Long COVID Phase 2 program.